Analyst Research Roundup: Seres Therapeutics, Inc. (MCRB), Surgery Partners, Inc. (SGRY)

Seres Therapeutics, Inc. (NASDAQ:MCRB) tinted gains of +0.33% (+0.02 points) to US$6. The volume of 0.16 Million shares climbed down over an trading activity of 102.64 Million shares. EPS ratio determined by looking at last 12 month figures is -2.62. Over the same time span, the stock marked US$10.32 as its best level and the lowest price reached was US$4.42. The corporation has a market cap of US$245.88 Million.

Seres Therapeutics, Inc. (NASDAQ:MCRB)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at 0 percent while most common profitability ratio return on investment (ROI) was -150.6 percent. The company’s institutional ownership is monitored at 78.9 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 1 think it is Hold. Recently, analysts have updated the overall rating to 1.83. 3 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Surgery Partners, Inc. (NASDAQ:SGRY) is worth US$685 Million and has recently risen 2.91% to US$13.1. The latest exchange of 0.15 Million shares is below its average trading activity of 249.48 Million shares. The day began at US$12.84 but the price moved to US$12.84 at one point during the trading and finally capitulating to a session high of US$13.32. The stock tapped a 52-week high of US$19.95 while the mean 12-month price target for the shares is US$18.25.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 1.1, and a price to sales ratio of 0.39. For the past 5 years, the company’s revenue has grown 38.8%, while the company’s earnings per share has grown -57.9%. With an institutional ownership near 99.7%, it carries an earnings per share ratio of -1.59.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 5 brokerage firms polled by Factset Research. At present, 3 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.78.